Seroatlas · Human Serome Atlas

RFLNB

Refilin-B

Also known as: Cfm1, FAM101B, MGC45871, RefilinB, RFLB_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N5W9
Gene: RFLNB
Ensembl: ENSG00000183688
Chromosome: 17
Canonical length: 214 aa
Protein class: Predicted intracellular proteins
Subcellular location: Plasma membrane,Actin filaments,Cytosol

OverviewNCBI Gene

Enables filamin binding activity. Predicted to be involved in several processes, including actin filament bundle organization; negative regulation of bone mineralization involved in bone maturation; and negative regulation of chondrocyte development. Predicted to act upstream of or within actin cytoskeleton organization and epithelial to mesenchymal transition. Predicted to be located in actin cytoskeleton and cytoplasm. Predicted to be active in actin filament bundle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

214 residues, UniProt reviewed canonical sequence.

>Q8N5W9|RFLNB
     1  MVGRLSLQDV PELVDAKKKG DGVLDSPDSG LPPSPSPSHW GLAAGGGGGE RAAAPGTLEP
    61  DAAAATPAAP SPASLPLAPG CALRLCPLSF GEGVEFDPLP PKEVRYTSLV KYDSERHFID
   121  DVQLPLGLAV ASCSQTVTCV PNGTWRNYKA EVRFEPRHRP TRFLSTTIVY PKYPKAVYTT
   181  TLDYNCRKTL RRFLSSVELE AAELPGSDDL SDEC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RFLNB can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.61
Highest tissue expression: 74 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 74 nTPM
adipose tissue: 19 nTPM
thymus: 16 nTPM
breast: 15 nTPM
colon: 13 nTPM
heart muscle: 13 nTPM

Single-cell type

choroid plexus epithelial cells: 18 nCPM
podocytes: 11 nCPM
neutrophil progenitors: 10 nCPM
neutrophils: 5.5 nCPM
ependymal cells: 5 nCPM
megakaryocyte progenitors: 3.9 nCPM

Immune cell

basophil: 202 nTPM
eosinophil: 81 nTPM
neutrophil: 36 nTPM
naive CD4 T-cell: 9.7 nTPM
plasmacytoid DC: 9.1 nTPM
naive CD8 T-cell: 8.7 nTPM

Brain region

choroid plexus: 21 nTPM
hippocampal formation: 5.6 nTPM
cerebral cortex: 4.7 nTPM
spinal cord: 4.4 nTPM
medulla oblongata: 4.2 nTPM
basal ganglia: 4.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.27
gnomAD pLI: 0.27

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

filamin binding

Cellular components

actin filament bundle

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RFLNB in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RFLNB as an antibody target. Whether an autoantibody or antibody against RFLNB could matter depends on whether native RFLNB is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RFLNB is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label RFLNB as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...